CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7057 result(s)

Funding and Access to Assistive Technologies

Last Updated: November 27, 2020
Result type: Projects in Progress
Report Type: Environmental Scan - Report

This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects...

Clinician Input and Feedback

Published on: October 29, 2020
Result type: General Content

Clinician group input is used by CADTH in all phases of the review, including the development of the review protocol, appraisal of evidence, and interpretation of the results. The clinician group input summary and individual submissions are included in the committee briefing materials. Input from clinicians is submitted to CADTH by groups or as...

liraglutide (Saxenda)

Last Updated: November 26, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: liraglutide
Indications: Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.

  • Brand Name: Saxenda
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0668-000
  • Project Status: Pending
  • Submission Type: Initial

budesonide (Jorveza )

Last Updated: November 26, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: budesonide
Indications: Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).

  • Brand Name: Jorveza
  • Manufacturer: AVIR Pharma Inc
  • Project Number: SR0666-000
  • Project Status: Active
  • Submission Type: Initial

Evidence on Medical Imaging

Last Updated: April 29, 2020
Result type: Resources

Here you'll find our most current and relevant products on medical imaging. We’ve selected the following materials to get you started: PET Diagnostic Imaging with Prostate-Specific Membrane Antigen for Prostate Cancer: A Review of Clinical Utility, Cost-Effectiveness, Diagnostic Accuracy, and Guidelines (Summary With Critical Appraisal, Nove...

Evidence Related to Oncology

Last Updated: July 17, 2019
Result type: Resources

Here you'll find an up-to-date collection of CADTH’s oncology-related products. The bundle includes reports and other resources on a variety of topics related to the diagnosis and treatment of cancer. CADTH has reviewed the evidence on various cancer treatments, screening and diagnostic technologies, and ways to manage symptoms associated with ...

CADTH Reimbursement Reviews

Published on: October 29, 2020
Result type: General Content

Once Health Canada has approved a drug for use in Canada, the country’s public drug programs and cancer agencies must decide if the drug will be eligible for public reimbursement. The CADTH reimbursement review process plays an important role in their decision-making processes. Through our review process, CADTH conducts thorough and objective e...

COVID-19 and the Surge in Virtual Care: Lessons Learned and Challenges to Come

Event Date: November 19, 2020
Result type: Events

Before COVID-19, virtual care was a topic of interest to many Canadians, but widespread uptake felt stubbornly out of reach. The pandemic changed everything and the delivery of virtual care surged almost overnight.  Health care providers, policy-makers, and patients are wondering if we can sustain the momentum and how we should best integr...